Acute myeloid leukemia (AML) is a genetically complex and heterogeneous set of diseases characterized by a diverse set of mutations 1 . Despite an increased understanding of the molecular basis of AML pathogenesis, overall survival of adult patients with AML has only improved modestly in the past 30 years 2 . Leukemia stem cells (LSCs) are a subpopulation characterized by a self-renewal capacity and an ability to recapitulate the phenotypic heterogeneity of the disease 3,4 . While somatic alterations in genetic and epigenetic mechanisms in leukemogenesis are intensively studied, how post-transcriptional and translational regulation of mRNA/protein expression influences leukemia progression and LSC function remains poorly defined. Posttranscriptional regulation provides the abundance and diversity of the proteome that can contribute to cell fate decisions. RBPs are the central arbiters of this complex regulatory process. Recently, RBPs have emerged as an important class of gene expression regulators in cancer and hematological malignancies 5, 6 . Mutations in genes that encode proteins involved in RNA processing and metabolism 7 such as DKC1 (ref. 
shRNA in leukemia cells from the bone marrow and spleen at day 0 and day 16 after transplantation (Supplementary Table 9 ). We ultimately recovered a pool of shRNAs with greater than 20-fold depletion, indicating strong selection against their expression during leukemia progression ( Fig. 1c and Supplementary Fig. 1c-f) . We prioritized the 24 top hits, each of which had at least five shRNAs that gave 20-fold depletion in both the bone marrow and spleen (Fig. 1d,e and Supplementary Table 10 ). GO analysis of the top genes showed significant enrichment for RBPs. The majority of the hits (20/24) were in the MSI2 protein-protein interaction group (pool 3), suggesting that these complexes are important for disease progression (Fig. 1f,g ). Among the top 24 scored genes, we selected 7 genes (of which 4 encode RBPs) for in vitro validation, including Syncrip, Caprin, Dyrk2, Hnrnpr, Cct3, Mybbp1, and Hnrnpa3 ( Fig. 1h and Supplementary  Fig. 1g ). For all of the genes tested, we confirmed knockdown and observed a reduction in colony formation ( Fig. 1i and Supplementary  Fig. 1h ). Additionally, MLL-AF9 leukemia cells were generally more sensitive to shRNA depletion than normal cells (c-Kit + -enriched cells from bone marrow), except for Dyrk2, which was equally depleted in both cell types (Fig. 1i) . These data suggest that a dysregulated RBP network is differentially required for leukemia cell survival in comparison to normal cells.
SYNCRIP is required for survival of leukemia cells
Of these in vitro-validated genes, Syncrip demonstrated the most differential effect (tenfold) in colony-forming ability between leukemia cells and normal c-Kit + -enriched cells. Thus, we focused our investigation on SYNCRIP (synaptotagmin-binding, cytoplasmic RNA-interacting protein; also known as NSAP1 or hnRNPQ1 in humans), which has three tandem RNA-recognition motifs and is implicated in regulation of RNA processing, transcript turnover, and protein translation [20] [21] [22] [23] . Several studies suggest that SYNCRIP may have a role in neuronal morphogenesis 24, 25 . Yet, the role for SYNCRIP in cancer or leukemia has not been studied. To further evaluate the effects of SYNCRIP depletion, we first confirmed that shRNAs specific for Syncrip resulted in the reduction of SYNCRIP levels by immunoblot in MLL-AF9-transformed leukemia cells ( Fig. 2a and Supplementary Fig. 2a ). SYNCRIP depletion in leukemic cells resulted in rapid increase in myeloid differentiation as demonstrated by increased Gr-1 and Mac-1, F480, and CD115 surface staining (Fig. 2b,c and Supplementary  Fig. 2b ,c) and cellular morphology (Fig. 2d) at day 4 after transduction. Significant change in c-Kit level was observed for SYNCRIPdepleted cells with one shRNA (shRNA 2) but not the other shRNA (shRNA 1) (Supplementary Fig. 2d ). SYNCRIP knockdown also resulted in apoptosis of leukemia cells at 5 d after transduction ( Fig. 2e and Supplementary Fig. 2e,f) , suggesting that differentiating cells subsequently underwent apoptosis. Of note, SYNCRIP function was not restricted to MLL-AF9-driven leukemia, as we observed a similar reduction in the colony formation of AML-ETO9a-driven leukemia cells depleted for SYNCRIP (Supplementary Fig. 2g,h) . We further performed shRNA-mediated depletion in MLL-AF9 leukemia cells and found a requirement for leukemia in vivo (Fig. 2f) , as diseased mice with SYNCRIP-shRNA-expressing leukemia cells selected for attenuated Syncrip knockdown ( Supplementary Fig. 2i,j) .
To rule out the potential for off-target effects from shRNA-mediated knockdown and test an additional leukemia line, we developed Syncrip guide RNAs (gRNAs) for CRISPR-Cas9-mediated deletion. RN2 mouse myeloid leukemia cells (MLL-AF9, NRAS G12D , and expressing rtTA-RN2 cells; ref. 26) were transduced with vectors expressing inducible (tetO) Cas9 and gRNAs specific for Syncrip or an empty vector (Cas9-EV) and sorted for GFP positivity after induction by doxycycline 8 6 8 VOLUME 49 | NUMBER 6 | JUNE 2017 Nature GeNetics A r t i c l e s (Dox). We observed reduced colony formation and proliferation with an increase in differentiation (Fig. 2g-i and Supplementary Fig. 2k ,l) in SYNCRIP-depleted RN2 cells. No significant change in the percentage of c-Kit high cells was observed upon SYNCRIP depletion (Supplementary Fig. 2m) . In mammalian cells, there are multiple isoforms of SYNCRIP (UniProtKB, O60506 human SYNCRIP/hnRNP Q). To identify the SYNCRIP isoforms present in leukemia cells, we overexpressed cDNAs encoding three different isoforms of SYNCRIP (hnRNP Q1, 562 amino acids; Q3, 623 amino acids; Q4, 527 amino acids) in RN2 cells. Immunoblot analysis demonstrated the existence of two SYNCRIP isoforms, with the dominant isoform being Q1 (562 amino acids) and the alternative, larger isoform being Q3 (623 amino acids) (Supplementary Fig. 2n ). Despite the aggressiveness of the RN2 MLL-AF9 leukemia cells, SYNCRIP overexpression increased colony-forming activity, indicating that SYNCRIP overexpression can potentiate leukemic cell growth ( Supplementary  Fig. 2o ). More notably, overexpression of the SYNCRIP dominant isoform (562 amino acids) in RN2 cells drove a more rapid leukemia in vivo (Fig. 2j) .
Consistent with an on-target effect of CRISPR-Cas9-mediated deletion of Syncrip, ectopic expression of human SYNCRIP could rescue the reduction in colony formation and reverse the increased differentiation resulting from SYNCRIP depletion (Fig. 2k,l and Supplementary Fig. 2p,q) . Therefore, our data strongly suggest that SYNCRIP is required for leukemic cell growth, cell survival, and maintenance of the undifferentiated state.
CRISPR-Cas9-mediated deletion of SYNCRIP impairs leukemogenesis but not normal hematopoiesis
To further assess the function of SYNCRIP in normal and malignant hematopoiesis in vivo, we developed mice deficient for SYNCRIP using a CRISPR-Cas9 approach (co-injection of gRNAs and Cas9 mRNA into the pronuclei of mouse zygotes). We then collected fetal liver cells from developed embryos in pseudo-mothers at embryonic day (E) 14 and determined fetal liver genotypes by PCR (Fig. 3a,b, Supplementary  Fig. 3a , and Supplementary Table 11 ). We performed analysis on confirmed wild-type and CRISPR-Cas9-mediated knockout samples and found equivalent frequencies of phenotypic hematopoietic In vivo screen hairpin representation A r t i c l e s stem cells (HSCs) in wild-type versus knockout animals ( Fig. 3c and Supplementary Fig. 3b ) and a modest increase in granulocytemacrophage colony-forming units (CFU-GM) in the knockout mice (Supplementary Fig. 3c) . We then performed analysis of SYNCRIP function during normal hematopoiesis in vivo by monitoring the engraftment efficiency of wild-type and knockout transplanted cells in recipient mice. We confirmed reduction of SYNCRIP protein expression in engrafted bone marrow cells from knockout as compared to wild-type recipients (Fig. 3d,e) . We observed no defect in engraftment of the knockout cells in primary transplant mice (Fig. 3f) . To determine whether SYNCRIP is required for development of leukemia in vivo, we then isolated LSK cells from the bone marrow of Syncrip wild-type and knockout primary transplanted mice, transduced them with MLL-AF9-GFP-expressing viruses, and injected GFP + MLL-AF9-transformed cells into recipient mice (Fig. 3g) . We also performed secondary bone marrow transplantation of Syncrip wild-type and knockout bone marrow cells into lethally irradiated mice and found a mild reduction in engraftment ( Fig. 3h,i) . On the other hand, MLL-AF9-transformed LSK cells derived from knockout recipients showed a delay in leukemogenesis in vivo when compared to cells from wild-type recipients (Fig. 3j) .
However, we found that expression of SYNCRIP was maintained when the animals died of leukemia ( Fig. 3k and Supplementary Fig. 3d ). These data imply that the CRISPR-driven knockout fetal liver samples were mosaic for wild-type Syncrip and Syncrip knockout, resulting in outgrowth of the residual leukemia cells with wild-type SYNCRIP. Overall, these data indicate at requirement for SYNCRIP for the development of leukemia in a genetic mouse model.
SYNCRIP is highly expressed in and essential for human leukemia cells
To define the role of SYNCRIP in human leukemia, we surveyed a previously published expression data set and found that SYNCRIP expression was elevated in patients with AML who had diverse genetic alterations in comparison to normal hematopoietic stem and 0.8 progenitor cells (Fig. 4a) 27 . We also found elevated expression of SYNCRIP in other hematological malignancies, including T-ALL and B-ALL with various genetic abnormalities (Supplementary Fig. 4a ).
High levels of SYNCRIP expression were also observed across multiple human myeloid leukemia cell lines in comparison to normal human CD34 + -enriched cord blood cells (CB-CD34 + cells) ( Supplementary  Fig. 4b ). We further validated that SYNCRIP was highly expressed at the protein level in human myeloid leukemia cell lines (10/11) and primary patient samples (5 patients) in comparison to CB-CD34 + cells (Fig. 4b,c) . To test the functional role of the increased SYNCRIP expression in leukemic cells, we transduced myeloid leukemia cells (MOLM13, NOMO-1, KASUMI-1, and NB4) with lentiviral shRNA vectors targeting SYNCRIP and obtained efficient knockdown of SYNCRIP with two independent shRNAs. Upon SYNCRIP depletion, we observed reduced cell proliferation and increased apoptosis coupled with increased myeloid differentiation, depending on the particular marker, in the AML cell lines (Fig. 4d-h and Supplementary Fig. 4c-h) . Overall, these data suggest an important role for SYNCRIP in different types of human myeloid leukemia driven by various oncogenic drivers.
SYNCRIP and MSI2 co-regulate LSC gene expression programs
To better understand the molecular function of SYNCRIP in leukemia, we performed RNA sequencing on MLL-AF9 leukemia cells transduced with shRNAs against Syncrip 4 d after transduction. The transcriptional profile of cells transduced with Syncrip shRNA was significantly altered, and the results obtained from two independent shRNAs were highly correlated (Supplementary Fig. 5a ).
We found 282 genes that were differentially expressed, where 57 were downregulated (Syncrip was ranked as the ninth most downregulated gene) and 225 were upregulated (log 2 (fold change) > 1.5, false discovery rate (FDR) < 0.01; Fig. 5a and Supplementary 30 , an LSC-related gene signature associated with good prognosis in AML 31 , and the myeloid development program 32 were significantly enriched for upregulated genes in SYNCRIP-depleted cells (Fig. 5b-d and Supplementary Table 16 ). Moreover, we found that MLL-AF9 direct targets were enriched for genes downregulated after SYNCRIP depletion (Fig. 5e,f) . Consistent with the MLL program being reversed upon Syncrip knockdown, genes negatively regulated by HOXA9 and MEIS1 were enriched for genes suppressed by SYNCRIP (Fig. 5g) . Overall, these data suggest that SYCNRIP depletion results in loss of the HSC/LSC program and the MLL-AF9 gene expression program. On the basis of previous studies 15 and our data, we hypothesized that SYNCRIP and MSI2 might co-regulate the LSC/MLL epigenetic program. Consistent with this observation, genes downregulated after SYNCRIP depletion were A r t i c l e s significantly enriched for direct mRNA binding targets for MSI2 (Top HITS-CLIP; cross-linking immunoprecipitation followed by high-throughput RNA sequencing targets 29 ) (Fig. 5h) . Furthermore, genes upregulated in SYNCRIP-depleted cells were enriched for genes that were also upregulated in Msi2-deleted LSCs 15 (Fig. 5i) . Interestingly, genes regulated by MSI2 including Hoxa9, Myc, Ikzf2, and Meis1 were found to be downregulated upon loss of SYNCRIP (Supplementary Fig. 5b ).
To evaluate the relevance of these data, we examined a human expression data set (Fig. 4a) and found that elevated SYNCRIP expression corresponded to an increase in HOXA9 and MEIS1 target genes, IKZF2 and MYC, without corresponding to altered MSI2 levels ( Supplementary Fig. 5c-g ). Taken together, these data suggest that SYNCRIP and MSI2 may co-regulate a gene expression program that is essential for myeloid leukemia cells.
SYNCRIP and MSI2 interact through shared mRNA targets
To further probe the interaction between SYNCRIP and MSI2, we performed reciprocal immunoprecipitations in MSI2-overexpressing K562 cells to confirm SYNCRIP as an interacting partner of MSI2, based on our mass spectrometry data. We detected the interaction by reciprocal immunoprecipitation using antibodies against either MSI2 or SYNCRIP. Interestingly, we found that the interaction was RNA dependent, as treatment of the lysate with RNase diminished the interaction of the two proteins (Fig. 6a) . A similar interaction was observed in MOLM13, a myeloid leukemia cell line carrying MLL-AF9 fusion protein (Supplementary Fig. 6a ). To investigate whether SYNCRIP and MSI2 share the previously validated targets of MSI2 in MLL-AF9-driven leukemia 15 , we performed RNA immunoprecipitation and found that SYNCRIP could also bind Myc, Hoxa9, and Ikzf2 mRNA (Fig. 6b) .
SYNCRIP regulates HOXA9 expression post-transcriptionally
Next, we sought to determine whether SYNCRIP regulates expression of these candidate genes. Targeted depletion of SYNCRIP with CRISPR-Cas9 or shRNA in multiple myeloid leukemia cells (RN2 cells, mouse dsRed MLL-AF9 cells, and MOLM13 cells) significantly reduced HOXA9 (Fig. 6c,d and Supplementary Fig. 6b-c) . A decrease in MYC and IKZF2 was observed with CRISPR-Cas9 depletion of SYNCRIP in RN2 cells (Fig. 6c) , while reduction in MYC was observed at 4 d after transduction in comparison to 3 d after transduction in both dsRed MLL-AF9 cells and MOLM13 cells (Fig. 6d  and Supplementary Fig. 6b,c) . While these changes occurred at the protein level, we also observed variable reductions in the mRNA levels of Hoxa9, Myc, and Ikzf2 (Supplementary Fig. 6d,e,h-j) . As previously described, MSI2 depletion reduced HOXA9 and MYC protein expression and downregulated Hoxa9, Myc, and Ikzf2 mRNA levels at 4 d after transduction, similar to the phenotype observed in SYNCRIP-knockdown cells (Supplementary Fig. 6f,g ).
To further understand the mechanism for SYNCRIP regulation of HOXA9 expression, we examined the effects of SYNCRIP depletion on total RNA but found no change in SYNCRIP-depleted cells in comparison to control cells (Supplementary Fig. 6k) . Additionally, reduced HOXA9, MYC, and IKZF2 protein levels in SYCNRIPdepleted cells were not due to an effect on mRNA stability, as the mRNA levels of these genes were equivalent after the addition of actinomycin D to block transcription (Supplementary Fig. 6l,m) . Moreover, measurement of newly synthesized proteins based on AHA incorporation showed a significant decrease in AHA-labeled HOXA9 protein in SYNCRIP-depleted cells. Despite its short halflife, MYC labeling at day 3 remained unchanged ( Fig. 6e) , and global peptide synthesis was modestly increased as determined by quantification of total OP-Puro incorporation (Fig. 6f,g ). These data suggest that SYNCRIP in part controls the translation of specific targets, including HOXA9.
HOXA9 is a functional target of SYNCRIP in leukemia cells
In support of SYNCRIP and MSI2 co-regulating the MLL-associated transcriptional program, MSI2 overexpression could rescue the reduced colony formation and reversed the reduction of HOXA9 after 
A r t i c l e s
shRNA-mediated Syncrip depletion ( Fig. 7a and Supplementary  Fig. 7a,b) . Verifying the functional relationship between SYNCRIP and HOXA9, retroviral HOXA9 overexpression partially reversed the reduction in colony formation of dsRed MLL-AF9 cells after SYNCRIP depletion (Fig. 7b,c and Supplementary Fig. 7c,d) . Similarly, overexpression of HOXA9 also rescued the cell growth in SYNCRIP-knockdown MOLM13 cells (Fig. 7d,e) . In contrast, forced MYC expression failed to rescue the effects of SYNCRIP depletion (Supplementary Fig. 7e-h) . Interestingly, MYC protein levels were also reduced after SYNCRIP depletion but remained higher than the controls after shRNA depletion. These data suggest that SYNCRIP regulates the translation of the MLL and LSC program in part through its control of HOXA9 expression.
To directly demonstrate the relevance of SYNCRIP function in human leukemia, we knocked down SYNCRIP expression in primary leukemia cells derived from a patient with AML (Supplementary  Table 17 ) by transducing cells with control shRNA or SYNCRIPtargeting shRNA. We monitored engraftment of the cells in vivo after transplantation of sorted GFP + transduced cells into recipient mice. Depletion of SYNCRIP protein expression resulted in a marked reduction in engraftment of human CD45 + GFP + double-positive leukemia cells at week 10 (for shRNA 1) and week 16 (for both shRNAs 1 and 2) (Fig. 7f) . Notably, HOXA9 expression in the primary AML cells correlated with the extent of SYNCRIP shRNAs depletion (Fig. 7g) . Altogether, these data indicate that SYNCRIP regulates myeloid leukemia cell proliferation at least in part through regulating the expression of HOXA9, a critical target in leukemia (Fig. 7h) .
DISCUSSION
Our study uncovered a functionally dysregulated riboproteomic network in myeloid leukemia by performing an in vivo shRNA screen for the MSI2 interactome. We identified several RBPs, including SYNCRIP, that were essential for the survival of myeloid leukemia cells. Other studies have used similar approaches to identify novel epigenetic regulators in leukemia, for example, BRD4 (ref. 33) , SIRT-1 (ref. 34) , and JMJ1c 19 , or to identify unknown functions of cancer-associated genes in leukemia, for example, ITGB3 (ref. 18) . We uncovered an RBP-associated network that allowed us to further explore the functional interactions between its components, in particular MSI2 and SYNCRIP. We found that MSI2 and SYNCRIP co-regulated the myeloid leukemia self-renewal post-transcriptional program, including many of the downstream targets of MLL-AF9, specifically, HOXA9 (Fig. 7h) . RBPs act in concert to orchestrate the regulatory processes of protein expression in a manner similar to that of many well-characterized functional complexes that mediate epigenetic regulation.
SYNCRIP binds and regulates the expression of the mRNA targets of MSI2, including Hoxa9, Ikzf2, and Myc. Mechanistically, we also demonstrated that SYNCRIP regulates synthesis of HOXA9 protein, one of the major functional downstream targets of the MLL-AF9 transcriptional program. These data indicate that SYNCRIP shares with MSI2 a set of common target genes, which are critical for leukemia. However, it is likely that SYNCRIP also controls expression of genes that are not associated with MSI2 or the MLL-associated network. Future studies that directly profile . Cells without OP-Puro incorporation served as staining controls. n = 4 independent experiments; error bars, s.e.m. *P < 0.05, **P < 0.001, ***P < 0.0001, two-tailed t test.
A r t i c l e s SYNCRIP's binding targets would further expand understanding of SYNCRIP's function in leukemia. The function of SYNCRIP in normal development and in cancer is poorly characterized. It has been mostly studied in the context of neuronal tissue and mRNA trafficking in neurons 20, 24, 25 . Only recently has SYNCRIP been implicated in exosomal microRNA (miRNA) sorting in hepatocyte cells 35 . Using both loss-and gain-of-function approaches in vitro and in vivo, we demonstrated a requirement for SYNCRIP as a novel cooperating oncogene in myeloid leukemia. We also created SYNCRIP-knockout cells with CRISPR-Cas9 by taking advantage of the unique ability of HSCs to engraft and reconstitute a recipient's blood system. This system demonstrated that SYNCRIP is differentially required in leukemia cells in comparison to normal cells. Nevertheless, it will be important to further study the role of SYNCRIP in hematopoiesis.
In human AML, SYNCRIP expression was elevated in AML cell lines and in patients in comparison to normal cells. This supports the differential requirements for SYNCRIP in leukemia cells versus normal cells, suggesting that SYNCRIP is a potential therapeutic target in AML. Interestingly, dysregulation of MSI2 in AML was previously described as a predictor of poor survival in MDS 36 and AML 12 , and future studies will determine whether SYNCRIP can similarly be a useful diagnostic marker in leukemia.
In summary, as the roles for RBPs in leukemia and cancer have become clinically relevant, these proteins represent a new class of targets for therapeutic interventions. Small-molecule inhibitors that specifically block RBP binding to RNAs or antisense oligonucleotides (ASOs) that can knock down these proteins could be potential strategies for targeting these RBP complexes [37] [38] [39] [40] . Overall, we propose that targeting the riboproteomic network in leukemia could be a new therapeutic strategy in cancer.
URLs. MSigDB, http://www.broadinstitute.org/msigdb.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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ONLINE METHODS
Mass spectrometry methods and analysis (for pool 3). K562 cells expressing either MSCV-IRES-GFP (control) or FLAG-MSI2 were grown in RPMI medium with 10% FBS. Immunoprecipitation with anti-FLAG antibody was performed as previously described 15 . Immunoprecipitate from 150 million cells per experiment was run on an SDS-PAGE gel and stained with Coomassie blue. The gel was then cut into six slices for the control or eight equal slices for FLAG-MSI2, except for the slice that encompassed MSI2 (slice 6), by the Children's Proteomics Core Facility and then run on a Thermo Fisher Orbitrap XL top 6 with data-dependent acquisition using a 60-min gradient. Control and MSI2-interacting proteins were considered to be represented if there were two or more peptides found and there was high confidence with a MASCOT score of equal to or greater than 20 or 77. Pairwise analysis was performed for two independent immunoprecipitation experiments and mass spectrometry analyses. TOPGENE was performed with 234 MSI2 direct binding targets.
Intestinal MSI1 CLIP-CHIP used for pool 2 gene prioritization. UVcrosslinked mouse intestinal cells were used for immunoprecipitation of MSI1 (ab5977, Millipore). The CLIP protocol was similar to that used in Park et al. 29 , with the exception that RNA was randomly primed and hybridized to the Affymetrix 1.0ST array. Fold enrichment was ranked over control IgG.
Pool description for the gene prioritization for the in vivo shRNA screen.
The number of genes used in our screen was determined on the basis of our previous studies, which included approximately 100 genes 22 . Therefore, the genes in each pool were prioritized according to the following criteria. Pool 1 was made up of two subpools, 1a and 1b. Pool 1a was composed of differentially expressed genes prioritized on the basis of Msi2 gene expression and other hematopoietic gene sets with a matrix score of 6 or greater (Supplementary Table 3 ). Pool 1b was selected on the basis of genes found in the leading edge taken from the GSEA with MSI2 overexpression in LSK cells overlapped with genes upregulated after shRNA depletion in CML/AML cell lines or leading-edge genes in the rank list of Msi2-knockout LSKs. Genes previously determined to be canonical targets, such as Numb, Numbl, and Cdkn1a, were added (Supplementary Table 4) . Pool 2 genes were chosen on the basis of an intestinal CLIP-CHIP assay (UV-crosslinked mouse intestine) in which MSI1 was immunoprecipitated. MSI1-bound targets were ranked for the top 1,000 genes, binding of the 3′ UTR, and fold enrichment over control IgG (Supplementary Table 5 ). These genes were ranked if they were MSI2 target genes and hematopoietic-relevant genes. A combined score of 3 or more was included into the screen (Supplementary Table 6 ).
Pool 3 included direct protein interactors of MSI2. A matrix score of 3 or more was chosen on the basis of the ability of proteins with this score to interact with MSI2 and was included in an MSI2 or hematopoietic-relevant gene set (Supplementary Table 7) . A list summarizing the genes included in the shRNA screen is provided in Supplementary Table 8. Lentiviral production, infection, and in vivo shRNA screen. Lentiviruses expressing shRNAs in the pLKO.1 vector were obtained from the RNAi consortium at the Broad Institute. Virus production and preparation of pooled and titered lentiviruses for screening were performed as previously described 18 . Pooled titered virus was thawed and kept on ice. L-GMPs (the top 50% of c-Kit high cells) were sorted. For infection, 600 µl of virus + 600 µl of cells (2 × 10 6 cells) per replicate were plated in 12-well dishes (1.2 ml/well). Cells were spinfected (768g for 90 min) and then split on day 0 for sequencing or injection into sublethally irradiated mice. Five pools with a random set of ~100 shRNAs per pool and a total of 627 titered shRNA viruses were generated and used to transduce leukemia cells. Each transduction well was split: half was kept for sequencing and half was used for transplantation (1 × 10 6 cells) into sublethally irradiated recipient mice. There were five replicates per pool with five mice per pool in an experiment including 25 mice in total. After 2 weeks, cells were collected from the bone marrow and spleen and, along with previously frozen cells, used for sequencing analysis.
Isolation, infection, and selection of mouse leukemia and normal cells. Tibia and femurs, pelvic bones, and arm bones from leukemic or wild-type C57BL/6 mice (6-8 weeks old) were collected, crushed, filtered and subjected to red blood cell lysis (Qiagen). To isolate c-Kit + cells, bone marrow cells were incubated with anti-CD117 Microbeads (Miltenyi Biotec), according to the manufacturer's instructions, and then subjected to positive selection using an autoMACS Pro Separator. Cells were spinfected in RPMI medium with 10% FBS and cytokines: SCF (10 ng/ml), IL-3 (10 ng/ml), IL-6 (10 ng/ml), and GM-CSF (10 ng/ml). 48 h after transduction, cells were treated with 2 µg/ml puromycin. Two days after the start of puromycin selection, cells were collected for further analysis.
Colony-forming assays. 10,000 cells were plated on MethoCult GFM3434 (Stemcell Technologies). Colonies were scored every 5 d for leukemia cells and every 7 d for normal c-Kit + -enriched bone marrow cells.
In vivo transplantation of leukemia cells. MLL-AF9 tertiary mouse leukemia cells were transduced with lentiviruses expressing a puromycin resistance gene and shRNAs against Syncrip or a control shRNA. Transduced cells were selected with 2 µg/ml puromycin for 2 d. 50,000 selected cells were injected retro-orbitally into female C57BL/6 recipient mice (6-8 weeks old) that had been sublethally irradiated with 475 cGy. All animal studies were performed on animal protocols approved by the Institutional Animal Care and Use Committee (IACUC) at the Memorial Sloan Kettering Cancer Center.
CRISPR-Cas9 approach to create Syncrip-knockout mice. The CRISPR gRNAs used to delete exons 3 and 4 of the Syncrip gene were designed using the approach of Romanienko et al. 41 . The sequence for the 5′ gRNA was 5′-GTACCTGTATTACCCAATGC-3′, and the sequence for the 3′ gRNA was 5′-CAATTTGGAATTGACCGCAC-3′. Both were produced by in vitro transcription using the pU6T7 promoter in the hybrid plasmid described. To initiate cleavage of the target locus in mice, gRNA C67 and gRNA C69 in conjunction with Cas9 mRNA were co-injected into the pronuclei of mouse zygotes at a concentration of 50 ng/µl each, using conventional techniques 43 . Deleted samples were assayed using PCR primers located outside of the gRNA cleavage sites (outside of Syncrip exons 3-4), thereby revealing the size of the deletion on the basis of the nucleotide length of the amplicon obtained (~900 bp for wild type versus ~300 bp for the deletion).
Isolation of fetal liver cells, PCR genotyping, and bone marrow transplantation. Fetal liver cells were isolated and placed in single-cell suspension according to standard protocols 42 . ~200,000 fetal liver cells after red blood cell lysis were used for DNA extraction with HotSHOT genomic DNA preparation methods. 2 µl of supernatant containing DNA was used for PCR reactions with primers specific for the detection of Syncrip exons 3-4. DNA was resolved on a 1.5% agarose gel. 500,000 cells from confirmed B6 CD45.2 + wild-type and Syncrip-knockout fetal livers were retro-orbitally injected into lethally irradiated B6 CD45.1 + Pep Boy, a C57BL/6 congenic strain carrying the differential Ptprca pan-leukocyte marker CD45.1, or Ly5.1 + recipient mice. For secondary transplantation, 1 million bone marrow cells were retro-orbitally injected into lethally irradiated CD45.1 + recipient mice.
Generation of MLL-AF9 primary leukemia and transplantation. Recipient mice at 6-10 weeks of age previously transplanted with cells from wild-type (WT) or CRIPSR-KO fetal livers (KO) were used. Bone marrow cells were isolated and subsequently enriched for c-Kit + cells. c-Kit + -enriched cells were stained with a lineage antibody cocktail (antibodies to CD3, CD4, CD8, Gr-1, B220, CD19, and Ter119 conjugated with PeCy5) and with Sca-Pac Blue, CD34-FITC, SLAM-APC, CD48-PE, and c-Kit-APC-Cy7 antibodies. LSK cells were sorted using a BD FACSAria instrument. Sorted cells were grown overnight in SFEM medium with 10 ng/ml IL-3, 10 ng/ml IL-6, 50 ng/ml SCF, 10 ng/ml thrombopoietin (TPO), and 20 ng/ml FLT3L. Cells were transduced twice with supernatant containing retroviruses encoding MLL-AF9 and GFP (a gift from S. Armstrong, Memorial Sloan Kettering Cancer Center) on retronectin-coated 96-well flat-bottom plates. The cells were expanded for 1 week in GFM3434 methylcellulose (Stemcell Technologies). MLL-AF9-transformed cells were sorted for GFP positivity. 200,000 GFP + cells and 250,000 helper cells were injected retro-orbitally into each lethally irradiated 6-to 8-week-old C57BL/6 mouse. using htseq-count (v0.6.0; parameter --t exon) and gene models from Ensembl (Mus_musculus.GRCm38.75.gtf). Differential expression analysis was performed using DESeq2 (v1.2.10; default parameters).
Statistical analysis. Student's t test was used for significance testing in the bar graphs, except where stated otherwise. A two-sample equal-variance model with normal distribution was used. The investigators were not blinded to the sample groups for all experiments. P values less than 0.05 were considered to be significant. Graphs and error bars reflect means + s.e.m., except where stated otherwise.
For animal studies, survival probabilities were estimated using the KaplanMeier method and compared with the log-rank test. Ten female mice per group were chosen to have an estimated 80% power in detecting a greater than 1.50 s.d. difference in means at a significance level of α = 0.05 using a two-sided test. All animals were randomly assigned to the experimental groups.
All statistical analyses were carried out using GraphPad Prism 4.0 and the R statistical environment.
Data availability. We used gene expression data sets previously published from Hemaexplorer 27 . RNA sequencing data in this study have been deposited into the Gene Expression Omnibus (GEO) under accession GSE74178. Mass spectrometry data are available from http://doi.org/10.5281/zenodo.375632.
